The TOMATO Study (Tacrolimus Metabolization in Kidney Transplantation): Impact of the Concentration–Dose Ratio on Death-censored Graft Survival

Background. Tacrolimus trough concentrations (mean/variability), as well as concentration-to-dose ratio (C/D ratio), affect kidney allograft outcomes. We investigated the link between the C/D ratio and death-censored kidney graft survival (DCGS). Methods. We performed a retrospective study on 1029 kidney transplant patients (2004–2016) with the following criteria: tacrolimus-based immunosuppression, >1-year graft survival, no initial use of everolimus, and available anti–human leukocyte antigen antibody data. We analyzed the impact of the time-varying C/D ratio on DCGS. Fast metabolizers were defined by a C/D ratio < 1.05. We also investigated the effect of an early (mo 3 to mo 6 post transplantation) C/D ratio below 1.05. Cox survival analyses were performed, adjusting for potential confounders (tacrolimus trough, variability of tacrolimus trough, de novo donor-specific antibody development, cytochrome P450 3A5 genotype, pregraft sensitization, mo 3 glomerular filtration rate). Results. Time-varying C/D ratio was significantly associated with DCGS (hazard ratio [HR], 2.35; P < 0.001) in a univariate model, on the full analysis set comprising 1029 patients. In the multivariate time-varying model, based on 666 patients with available cytochrome P450 3A5 genotypes, the effect of the C/D ratio remained significant (HR, 2.26; P = 0.015); even when glomerular filtration rate at month 3 < 30 mL/min/1.73 m2 (HR, 2.61; P = 0.011), de novo donor-specific antibody development (HR, 4.09; P < 0.001) and continued steroid prescription (HR=2.08, P = 0.014) were taken into account (other covariates, including tacrolimus trough concentrations, were nonsignificant). In the same multivariate model, the effect of early C/D ratio (median at mo 3 and mo 6) remained significantly associated with DCGS (HR, 2.25; P = 0.041). Conclusions. C/D ratio is an independent and early predictor of DCGS. Identification of fast metabolizers could be a strategy to improve graft survival, for example, by optimizing tacrolimus formulation. Mechanistic studies to understand the C/D ratio effect are required.

[1]  Reuter,et al.  Fast Tac Metabolizers at Risk—It is Time for a C/D Ratio Calculation , 2019, Journal of clinical medicine.

[2]  R. Tsonaka,et al.  Pitfalls of linear regression for estimating slopes over time and how to avoid them by using linear mixed-effects models. , 2019, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  A. Åsberg,et al.  High tacrolimus clearance – a risk factor for development of interstitial fibrosis and tubular atrophy in the transplanted kidney: a retrospective single‐center cohort study , 2018, Transplant International.

[4]  F. Lemaitre,et al.  Pharmacogenetics of Membrane Transporters of Tacrolimus in Solid Organ Transplantation , 2018, Clinical Pharmacokinetics.

[5]  D. Kuypers,et al.  Relationship between In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Systemic Tacrolimus Metabolite/Parent Drug Ratio in Renal Transplant Recipients and Healthy Volunteers , 2018, Drug Metabolism and Disposition.

[6]  L. Pączek,et al.  Evaluation of the Relationship Between Concentrations of Tacrolimus Metabolites, 13-O-Demethyl Tacrolimus and 15-O-Demethyl Tacrolimus, and Clinical and Biochemical Parameters in Kidney Transplant Recipients. , 2018, Transplantation proceedings.

[7]  L. Rostaing,et al.  Tailoring tacrolimus therapy in kidney transplantation , 2018, Expert review of clinical pharmacology.

[8]  D. Brennan,et al.  Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients. , 2018, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  A. Åsberg,et al.  High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal Transplantation , 2017, Transplantation.

[10]  L. Rostaing,et al.  New formulations of tacrolimus and prevention of acute and chronic rejections in adult kidney-transplant recipients , 2017, Expert opinion on drug safety.

[11]  L. Rostaing,et al.  Reduction of Extended‐Release Tacrolimus Dose in Low‐Immunological‐Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor‐Specific Antibodies: A Randomized Study , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  S. Brouard,et al.  Failure of Calcineurin Inhibitor (Tacrolimus) Weaning Randomized Trial in Long‐Term Stable Kidney Transplant Recipients , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  S. Knight Intrapatient variability in tacrolimus exposure – a useful tool for clinical practice? , 2016, Transplant international : official journal of the European Society for Organ Transplantation.

[14]  M. Arias,et al.  Within-Patient Variability in Tacrolimus Blood Levels Predicts Kidney Graft Loss and Donor-Specific Antibody Development , 2016, Transplantation.

[15]  L. Pączek,et al.  Tacrolimus Metabolite M-III May Have Nephrotoxic and Myelotoxic Effects and Increase the Incidence of Infections in Kidney Transplant Recipients. , 2016, Transplantation proceedings.

[16]  V. Haufroid,et al.  Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive Drugs , 2016, Therapeutic drug monitoring.

[17]  C. O’Seaghdha,et al.  Tacrolimus trough-level variability predicts long-term allograft survival following kidney transplantation , 2016, Journal of Nephrology.

[18]  S. Aliño,et al.  Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies , 2014, The Pharmacogenomics Journal.

[19]  H. Gerth,et al.  The Tacrolimus Metabolism Rate Influences Renal Function after Kidney Transplantation , 2014, PloS one.

[20]  S. Kim,et al.  Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure. , 2014, Kidney international.

[21]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[22]  W. Weimar,et al.  High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[23]  P. Halloran,et al.  Calcineurin Inhibitor Minimization in the Symphony Study: Observational Results 3 Years after Transplantation , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[24]  橋本光男,et al.  腎移植におけるDSA(Donor specific antibody)陽性症例の検討 , 2008 .

[25]  M. Guba,et al.  Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation , 2018 .

[26]  P. Halloran,et al.  Reduced exposure to calcineurin inhibitors in renal transplantation. , 2007, The New England journal of medicine.

[27]  U. Christians,et al.  Tacrolimus (FK506) metabolite patterns in blood from liver and kidney transplant patients. , 1996, Clinical chemistry.